Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | LIG1 | P18858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8331926 | 0.84 | NOTUM (0.46) | NOTUMNPSR1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8331929 | 0.84 | NOTUM (0.46) | NOTUMNPSR1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2257179 | 0.76 | NOTUM (0.46) | NOTUMCES1LIG1MAPTALDH1A1 | |
| SCHEMBL8328296 | 0.73 | NOTUM (0.46) | NOTUMCES1LIG1MAPTALDH1A1 | |
| SCHEMBL5893933 | 0.69 | NOTUM (0.51) | NOTUMMAPTALDH1A1SMN1; SMN2CYP11B2 | |
| SCHEMBL8326465 | 0.66 | CES1 (0.40) | CES1DAO | |
| SCHEMBL7163398 | 0.65 | NOTUM (0.69) | NOTUMMAPTALDH1A1CYP11B2 | |
| SCHEMBL26777824 | 0.65 | NOTUM (0.63) | NOTUMCYP11B2 | |
| SCHEMBL19219782 | 0.65 | NOTUM (0.63) | NOTUMNPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12559558 | 0.65 | NOTUM (0.65) | NOTUMMAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994333-B2 | Methods and compositions for selectin inhibition | WYETH LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994333-B2 | Methods and compositions for selectin inhibition | WYETH LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994333-B2 | Methods and compositions for selectin inhibition | WYETH LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090069564-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069564-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069564-A1 | Methods and Compositions for Selectin Inhibition | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-7465798-B2 | Methods and compositions for selectin inhibition | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465798-B2 | Methods and compositions for selectin inhibition | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465798-B2 | Methods and compositions for selectin inhibition | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080125454-A1 | preventing selectin-mediated leukocyte adhesion to the vascular endothelium; 2-(4-Chloro-phenyl)-3-hydroxy-benzo[h]quinoline-4-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-h]quinoline-6-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-9-aza-cyclopenta[a]naphthale | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125454-A1 | preventing selectin-mediated leukocyte adhesion to the vascular endothelium; 2-(4-Chloro-phenyl)-3-hydroxy-benzo[h]quinoline-4-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-h]quinoline-6-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-9-aza-cyclopenta[a]naphthale | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008043075-A2 | COMPOSITIONS FOR THE TREATMENT OF SCLERITIS | WYETH (US) | 2008-04-10 | — | — | WO | disclosed |
| EP-1682510-A2 | METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION | Wyeth (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005047258-A2 | METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION | WYETH (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101569-A1 | Methods and compositions for selectin inhibition | WYETH (US) | 2005-05-12 | — | — | US | disclosed |
| EP-0529636-B1 | Novel isatinoxime derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1999-06-23 | — | — | EP | disclosed |
| US-5436250-A | Isatineoxime derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1995-07-25 | — | — | US | disclosed |
| US-5242918-A | Isatinoxime derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-09-07 | — | — | US | disclosed |
| WO-1993005043-A1 | NOVEL ISATINOXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1993-03-18 | — | — | WO | disclosed |
| EP-0529636-A1 | Novel isatinoxime derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125454-A1 | preventing selectin-mediated leukocyte adhesion to the vascular endothelium; 2-(4-Chloro-phenyl)-3-hydroxy-benzo[h]quinoline-4-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-pyrrolo[3,2-h]quinoline-6-carboxylic acid; 8-(4-Chloro-benzyl)-7-hydroxy-2,3-dihydro-1H-9-aza-cyclopenta[a]naphthale | SELL, VCAM1, SELE | NOTUM 4025/4885NPSR1 348/4885CES1 641/4885 |
| US-20090069564-A1 | Methods and Compositions for Selectin Inhibition | SELP, SELE, SELL | NOTUM 2276/4885NPSR1 268/4885CES1 707/4885 |
| US-20050101569-A1 | Methods and compositions for selectin inhibition | SELP, SELE, SELL | NOTUM 2276/4885NPSR1 268/4885CES1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.